Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
about
Tegaserod for the treatment of irritable bowel syndrome and chronic constipationTegaserod for the treatment of irritable bowel syndromeThe effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.Review article: the safety profile of tegaserod.Tegaserod for constipation-predominant irritable bowel syndrome.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Recent advances in pharmacological treatment of irritable bowel syndrome.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersTreating irritable bowel syndrome: overview, perspective and future therapies.Pharmacology of serotonin: what a clinician should know.Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom.Review of tegaserod in the treatment of irritable bowel syndrome.Review article: tegaserod -- the global experience.Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.Recognizing and managing patients with irritable bowel syndrome.Tegaserod-associated ischemic colitis.The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.Emerging drugs for irritable bowel syndrome.Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatmentTegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.Meta-analysis: The treatment of irritable bowel syndrome.A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.Tegaserod in the treatment of irritable bowel syndrome with constipation.Tegaserod-induced myocardial infarction: case report and hypothesis--an alternative viewpoint.Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study.Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension.Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.Use of tegaserod along with polyethylene glycol electrolyte solution for colonoscopy bowel preparation: a prospective, randomized, double-blind, placebo-controlled study.
P2860
Q24242922-3D79A951-A785-4EFB-AA9A-7787E06F96EBQ24247426-C5BA5DF8-0ADF-4B2D-9C38-E183109CAFC4Q33431815-5988E8D1-B1C3-41E8-B168-F6BB869FEAC6Q33432438-0AD069CB-E272-432A-9045-C8B35018857FQ33436477-4E885ABA-BD52-4A3C-B328-97FF27DD367FQ33451900-583A7582-ACEE-437A-8FD1-6F3B328429D5Q33854983-30C2AEF3-2E54-4796-B0B6-179A2CDF082AQ33958853-5B5A95CC-672F-4272-9A0A-5CC606490C18Q34166903-FCF6B64E-581B-4CF5-895F-D5CD9D60319EQ35047051-7E55230E-ACA7-4F04-9956-31A5C27890CCQ35596862-31202D56-A0C7-4EDE-8489-294014566E1FQ35919167-36BD6C4A-3274-401F-9564-6332525EAB95Q35925555-078AE915-1681-4C1B-9508-04E4D6AFF45AQ35936942-B80548AF-6A9D-4ADD-8FC3-9A1C8879FBF9Q35971357-E51D4C51-6628-4CE5-8714-C970737DE6D4Q35985391-EBB73E10-CB81-476B-A334-2EBB84E419DFQ36044756-B1BB1BD1-3116-4A95-92FD-D86E01E97C72Q36174477-C27BC29D-B015-43F4-9411-C206D2AF57E9Q36407290-6DA5E896-BC56-4426-970A-ADD3A138D087Q36458417-4596B456-D528-4F02-9139-D4A1E7EAF1A2Q36536709-8FBE4CB8-BBED-4C25-87A2-3E3A4EBA8E55Q36803795-54B8A98E-56D4-407E-B707-9945A7823FDAQ39372044-0F525466-DBF9-4CC6-A07C-9DB2DD2841D6Q39372719-ACED64CD-5EA3-492C-913B-5188406905FAQ39383671-EFC839B3-9A0B-49A9-916B-9B6580F86054Q43267055-B652725B-DE66-4989-95F4-79C096E39706Q45146736-34CCCF43-0212-4C64-A829-B1BF09B76038Q45929234-FC848EF2-54A0-4DB4-BDCE-30EF28F63014Q46863112-14F981B7-C096-4CB7-B854-F316C0715CA8Q46879620-041645DD-8FED-44FF-9C74-D826FB7D0FBBQ46946139-D370995A-DC33-4C2C-AC7F-62072BA0643C
P2860
Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Long-term safety of tegaserod ...... nant irritable bowel syndrome.
@ast
Long-term safety of tegaserod ...... nant irritable bowel syndrome.
@en
type
label
Long-term safety of tegaserod ...... nant irritable bowel syndrome.
@ast
Long-term safety of tegaserod ...... nant irritable bowel syndrome.
@en
prefLabel
Long-term safety of tegaserod ...... nant irritable bowel syndrome.
@ast
Long-term safety of tegaserod ...... nant irritable bowel syndrome.
@en
P2093
P2860
P1476
Long-term safety of tegaserod ...... nant irritable bowel syndrome.
@en
P2093
Earnest DL
Langaker KE
Rojavin MA
Snape WJ Jr
P2860
P304
P356
10.1046/J.1365-2036.2002.01347.X
P407
P577
2002-10-01T00:00:00Z